Neuroimaging correlates with neuropathologic schemes in neurodegenerative disease
Neuroimaging correlates with neuropathologic schemes in neurodegenerative disease
复制标题
DOI:
10.1016/j.jalz.2019.03.016
复制
发表时间:
2019-07-01
影响因子:
14
通讯作者:
Murray, Melissa E.
中科院分区:
文献类型:
--
作者:
Lowe, Val J.;Lundt, Emily S.;Murray, Melissa E.
Introduction: Neuroimaging biomarkers are important for early diagnosis of Alzheimer's disease, and comparing multimodality neuroimaging to autopsy data is essential.Methods: We compared the pathologic findings from a prospective autopsy cohort (n = 100) to Pittsburgh compound B PET (PiB-PET), F-18-fluorodeoxyglucose PET (FDG-PET), and MRI. Correlations between neuroimaging biomarkers and neuropathologic schemes were assessed.Results: PiB-PET showed strong correlations with Thal amyloid phase and Consortium to Establish a Registry for Alzheimer's Disease score and categorized 44% of Thal phase 1 participants as positive. FDG-PET and MRI correlated modestly with Braak tangle stage in Alzheimer's type pathology. A subset of participants with "none" or "sparse" neuritic plaque scores had elevated PiB-PET signal due to diffuse amyloid plaque. Participants with findings characterized as "suspected non-Alzheimer's pathophysiology" represented 15% of the group.Discussion: PiB-PET is associated with Alzheimer's disease, neuritic plaques, and diffuse plaques. FDG-PET and MRI have modest correlation with neuropathologic schemes. Participants with findings characterized as suspected non-Alzheimer's pathophysiology most commonly had primary age-related tauopathy. (C) 2019 the Alzheimer's Association. Published by Elsevier Inc. All rights reserved.